Best AI pathology platforms, for cancer detection
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.
- 17
- 17
- May 23, 2026
Which pathology are worth shortlisting in 2026?
Four tools survived our 2026 review for clinical use: Tempus Digital Pathology for paige acquisition (aug 2025); PathAI AISight for open ims + ai platform; Proscia Concentriq for pharma r&d labs; Ibex Medical Analytics for deployed globally.
Four tools we actually recommend
Each pick wins a specific use case. The wrong question is “which is best”. The right question is “which fits my situation”. Skip past the ones not matching yours.
by Tempus AI
Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI.
NASDAQ:TEM. Most clinical-validation depth. FDA + CE-IVDR cleared modules.
- Enterprise + per-test.
- FDA 510(k) / CE-IVDR
by PathAI
Open IMS with AISight Dx + biopharma diagnostic services.
Vendor-agnostic IMS appeals to mixed-vendor labs. Strong biopharma R&D revenue.
- Enterprise.
- —
by Proscia
Used by 16/20 top pharma. $130M total funding.
IMS platform + AI marketplace. Strongest pharma R&D footprint.
- Enterprise.
- —
by Ibex
Most-deployed AI pathology platform globally.
Israeli-origin. Prostate, breast, colon focus. Broad EU + US deployments.
- Enterprise.
- —
What should clinicians look for when buying pathology?
The right tool depends on your workflow, your specialty, your budget, and your scale. Five criteria do most of the work narrowing your shortlist.
Workflow integration depth
How deeply does it sit inside your existing workflow? Tools that require copy-paste eventually get abandoned. Tools with native bidirectional sync into your EHR or platform stay.
HIPAA + compliance attestation
Non-negotiable for any clinical use. Look for explicit HIPAA + SOC2 + signed BAA. Free general-purpose LLMs are NOT compliant out-of-the-box.
Pricing transparency
Vendors that publish per-seat or per-encounter pricing on their site are easier to evaluate than enterprise-only quotes. If you can't get pricing without a sales call, factor that friction in.
Specialty and language fit
Performance varies materially by specialty and patient population. Aggregated reviews often look fine but mask specialty-level variance. Pilot in your own workflow before committing.
Vendor stability
This is a multi-year commitment in practice. Funding stage, leadership continuity, enterprise references, and platform partnerships matter. Pre-Series-B vendors carry more risk.
How do all 17 platforms compare side-by-side?
Pricing from vendor documentation, certifications verified against public attestations. Highlighted rows were directly evaluated by an MD on our editorial team within the past six months.
| Ref | Tool | From | Founded | Compliance / EHR | Action |
|---|---|---|---|---|---|
| PA-001 | Enterprise. | — | CE-IVDR | Visit | |
| PA-002 |  | Enterprise (biopharma). | — | Visit | |
| PA-003 |  | Enterprise. | — | Visit | |
| PA-004 |  | Enterprise. | — | Visit | |
| PA-005 |  | Enterprise. | — | Visit | |
| PA-006 |  | Enterprise. | — | Visit | |
| PA-007 | Enterprise. | — | Visit | ||
| PA-008 |  | Enterprise. | — | Visit | |
| PA-009 |  | Enterprise. | — | Visit | |
| PA-010 |  | Enterprise. | — | Visit | |
| PA-011 |  | Enterprise (biopharma + clinical). | — | Visit | |
| PA-012 | Enterprise. | 2016 | Visit | ||
| PA-013 |  | Enterprise. | — | Visit | |
| PA-014 |  | Enterprise. | — | Visit | |
| PA-015 | Enterprise. | — | Visit | ||
| PA-016 |  | Enterprise + per-test. | — | FDA 510(k)CE-IVDR | Visit |
| PA-017 |  | Enterprise per-module. | — | FDA 510(k)CE-IVDR | Visit |
Scroll horizontally to see all columns.
Where pathology touch the rest of the stack
What do clinicians ask about pathology?
Sourced from pathologists, lab directors, and KLAS digital pathology 2026 review.
Browse all questionsDeeper articles
Best AI Study Tools for USMLE Step 1 in 2026
Step 1 has been pass/fail since 2022, but the content load hasn't shrunk. We compare UWorld, AMBOSS, Anki/AnKing, SketchyMedical, and Pathoma for medical students preparing in 2026.
Read article
AI for Prior Authorization in 2026: Cohere, Waystar, and the State of Automation
Prior authorization remains the most expensive friction in US revenue cycle. We map the AI vendors closing that gap in 2026: Cohere Health on the payer side, Waystar on provider RCM, and the realistic state of automation.
Read article
Heidi Health vs Freed AI: Head-to-Head for Solo Clinicians (2026)
Both cost around $99 a month, both are HIPAA compliant, both work in a browser. We compared Heidi Health and Freed AI on note quality, template flexibility, language support, and onboarding for solo practice.
Read article